- ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.
Tech, healthcare slide weighs on rest of markets.
Healthcare's slide weighs on rest of markets.
The stock has been on fire.
If one of the two were to successfully acquire the company, it would get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer.